Like most organizations around the world, Lilly has been closely monitoring the COVID-19 pandemic and its global impact. We are working in line with Government guidance in the UK, and our first priority is to meet our responsibility to protect the health of our people, our customers and our communities.
Lilly does not anticipate shortages for any of our products, including all forms of insulin. Since the initial outbreak, Lilly has been closely monitoring our supply chain for potential impact to the supply of our medicines around the world. Globally, our manufacturing network is fully operational and as the global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicine.
Information on what Lilly is doing globally to make sure our employees and their families are safe, and to ensure people can access Lilly medicines, is available from our corporate website at Lilly.com